XNAS · Healthcare · Biotechnology
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 0.17 | 0.08 | -51.18% | $896.0M | ❌ Miss | -2.33% | -0.59% | — |
| 2026-02-17 | Q4 2025 | 0.44 | 0.05 | -88.64% | $1.06B | ❌ Miss | -2.80% | -2.00% | -14.23% |
| 2025-11-06 |
| Q3 2025 |
| 0.46 |
| 0.65 |
| +40.43% |
| $1.02B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 0.36 | 0.54 | +50.56% | $925.0M | ✅ Beat | -5.55% | +1.28% | +21.38% |
| 2025-02-12 | Q4 2024 | 0.28 | 0.85 | +203.57% | $921.6M | ✅ Beat | +6.25% | +11.58% | +4.16% |
| 2024-11-06 | Q3 2024 | 0.35 | 0.29 | -17.14% | $816.0M | ❌ Miss | +3.49% | -3.00% | -2.33% |
| 2024-08-08 | Q2 2024 | 0.33 | 0.31 | -6.06% | $779.5M | ❌ Miss | -2.36% | +0.52% | +1.44% |
| 2024-05-02 | Q1 2024 | 0.14 | 0.29 | +107.14% | $600.4M | ✅ Beat | +7.21% | +3.93% | +4.00% |
Showing last 8 quarters.